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Abstract
Background:  Colorectal cancer develops through two main genetic instability pathways
characterized by distinct pathologic features and clinical outcome.
Results: We investigated colon cancer samples (23 characterized by microsatellite stability, MSS,
and 16 by high microsatellite instability, MSI-H) for genome-wide expression of microRNA
(miRNA) and mRNA. Based on combined miRNA and mRNA gene expression, a molecular
signature consisting of twenty seven differentially expressed genes, inclusive of 8 miRNAs, could
correctly distinguish MSI-H versus MSS colon cancer samples. Among the differentially expressed
miRNAs, various members of the oncogenic miR-17-92 family were significantly up-regulated in
MSS cancers. The majority of protein coding genes were also up-regulated in MSS cancers. Their
functional classification revealed that they were most frequently associated with cell cycle, DNA
replication, recombination, repair, gastrointestinal disease and immune response.
Conclusion:  This is the first report that indicates the existence of differences in miRNA
expression between MSS versus MSI-H colorectal cancers. In addition, the work suggests that the
combination of mRNA/miRNA expression signatures may represent a general approach for
improving bio-molecular classification of human cancer.
Background
Colorectal cancer develops through two main genetic
pathways characterized by different forms of genomic
instability [1]. Most tumors are generated by the chromo-
somal instability (CIN) pathway and display marked
cytogenetic abnormalities, aneuploidy and allelic losses at
multiple chromosomal arms. CIN is probably caused by
various molecular mechanisms, but the underlying
genetic alterations are still poorly defined. About 15% of
colorectal carcinomas develop through the microsatellite
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instability (MSI) pathway. MSI tumors show stable karyo-
type, low frequencies of allelic losses and diploid nuclear
DNA content. MSI results from defects in the DNA mis-
match repair system (MMR) [2]. In HNPCC, MSI is pro-
duced by germline mutations of one of the MMR genes
(MLH1, MSH2 and less frequently MSH6 and PMS2) with
somatic inactivation of the wild-type allele [3,4]. In spo-
radic tumors, MMR deficiency is near always determined
by epigenetic inactivation of the MLH1 gene by biallelic
promoter methylation [5-7]. MSI colorectal adenocarci-
nomas display distinctive pathologic features, such as
proximal location, poor differentiation, frequent muci-
nous and medullary phenotype, and marked peritumoral
and intratumoral lymphocytic infiltration [8-10]. MSI car-
cinomas have a more favorable clinical outcome than
non-MSI tumors and the survival advantage conferred by
the MSI phenotype is independent of tumor stage and
other clinical and pathological variables [11-13]. In addi-
tion, MMR-deficient cancer cells are thought to be less
responsive to 5-fluorouracil and other chemotherapeutic
agents in vitro and in vivo [14-16].
Gene expression analysis based on genome-wide microar-
rays has been largely used to characterize human cancers.
This approach allowed the identification of genes impor-
tant in tumorigenesis. Furthermore, the discovery of gene
expression signatures characteristic of distinctive clinico-
pathological features suggested that expression profiles
could be used for molecular classification of human can-
cer [17-20]. Microarray tools have been recently enriched
by the development of platforms for the analysis of micro-
RNAs (miRNA) expression [21,22]. miRNAs are a class of
small non-coding RNAs involved in temporal and tissue-
specific eukaryotic gene regulation [23]. Comparison
between human cancers and their normal counterparts
revealed that miRNAs exhibit differential expression pro-
files in normal versus cancer tissues [24-29]. These studies
revealed that some human miRNAs are consistently dereg-
ulated in human cancer, suggesting a role in tumorigene-
sis either as oncogenes or tumor suppressor genes [30-32].
Unique miRNA expression signatures were found to be
associated with bio-molecular and prognostic characteris-
tics of human lung cancer and chronic lymphocytic leuke-
mia [24,33], indicating that miRNA signatures could be
used to define biological or clinical features of human
cancers. Known function of mammalian miRNAs is to
post-transcriptionally regulate target mRNAs, implying
that the combination of miRNAs and mRNAs expression
may better represent the transcriptional program that dic-
tates normal and tumor cell characteristics. Here, we iden-
tified differentially expressed miRNAs and mRNAs able to
distinguish colon cancers with or without microsatellite
instability.
Results
We analyzed miRNA and mRNA expression using micro-
arrays in a set of microsatellite stable (MSS) and unstable
(MSI-H) colorectal cancers (23 MSS and 16 MSI-H) (Table
1) with the aim of recognizing the most significant differ-
ences in gene expression. In particular, this is the first
study that investigates the differences in miRNAs expres-
sion between MSS and MSI tumors.
We carried out initial studies on miRNA and mRNA-chip
data separately. The analysis of miRNA expression profiles
of MSI-H versus MSS tumors identified 14 differentially
expressed miRNAs (p < 0.05). Additional file 1 provides
the list of deregulated miRNAs and their mean expression
values and standard errors in the two groups. The analysis
of mRNA expression profiles of MSI-H versus MSS identi-
fied a large number of differentially expressed genes (451
genes at p < 0.05; Additional file 2). By using the more
Table 1: Clinical and bio-pathological features of colorectal 
carcinomas employed in the study.
Feature No. MSS (%) MSI-H (%) P-value*
Sex
Male 21 15 (65.2) 6 (37.5) NS
Female 18 8 (34.8) 10 (62.5)
Age (years)
<55 3 2 (8.7) 1 (6.3) NS
55–70 11 9 (39.1) 2 (12.5)
>70 25 12 (52.2) 13 (81.3)
Tumor site
Proximal 
colon
18 5 (21.7) 13 (81.3) <0.001
Distal colon 21 18 (78.3) 3 (18.7)
Tumor stage 
(TNM)
I 2 1 (4.3) 1 (6.3) NS
II 16 9 (39.2) 7 (43.8)
III 13 7 (30.4) 6 (37.5)
IV 8 6 (26.1) 2 (12.5)
Tumor type
Adenocarcin
oma
29 22 (95.7) 7 (43.7) <0.001
Mucinous 
adenocarcino
ma
10 1 (4.3) 9 (56.3)
Grade of 
differentiation
Well/
moderate
29 22 (95.7) 7 (43.7) <0.001
Poor 10 1 (4.3) 9 (56.3)
MMR protein 
expression
MLH1 
negative
15 0 15 (93.8) <0,001
MSH2 
negative
10 1( 6 . 2 )
MLH1/MSH2 
positive
23 23 (100) 0
* Evaluated with Chi-square test or the Fisher's Exact test
NS, not significantMolecular Cancer 2007, 6:54 http://www.molecular-cancer.com/content/6/1/54
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stringent Bonferroni multiple testing correction at p <
0.05, a sub-list of 72 differentially expressed mRNAs was
identified (Additional file 3).
To visually assess the ability of the differentially expressed
miRNAs and mRNAs to distinguish MSS versus MSI-H
tumors, we applied the combination of the 86 differen-
tially expressed miRNAs and mRNAs to perform a super-
vised cluster analysis. Using this combined set of genes, a
perfect classification of the tumor samples resulted (Fig-
ure 1). The combination of the two sets of genes resulted
also in an improvement in the separation of the MSS ver-
sus the MSI tumor samples in comparison to the individ-
ual sets (see Additional files 4 and 5).
A smaller selected signature of best predictors of microsat-
ellite status was generated by applying Support Vector
Machine (SVM) (GeneSpring software) and Prediction
Analysis of Microarrays (PAM) algorithms to the 86 differ-
entially expressed miRNAs and mRNAs: 27 genes (inclu-
sive of mRNAs and miRNAs) were identified as predictors
by at least one of the two algorithms (Table 2). Cluster
analysis with these 27 miRNA/mRNAs still produced a
perfect separation between the two tumor classes, and a
Supervised hierarchical clustering of 39 colon cancer samples (23 MSS and 16 MSI-H) using expression data from the list of 86  differentially expressed mRNA/miRNA genes described in Supplemental Tables 1 and 3 Figure 1
Supervised hierarchical clustering of 39 colon cancer samples (23 MSS and 16 MSI-H) using expression data from the list of 86 
differentially expressed mRNA/miRNA genes described in Supplemental Tables 1 and 3. Columns display the clustering of 
tumor samples; rows the clustering of genes. MSI status is indicated by colored squares: red for MSS and yellow for MSI-H 
tumor samples. All sample were properly assigned to the correct class. The expression intensity of each gene in each sample 
varies from red to green: red color means an expression value over the average across samples, green color the opposite. For 
quantification of color codes, see color-bar on the right.Molecular Cancer 2007, 6:54 http://www.molecular-cancer.com/content/6/1/54
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Table 2: Predictors of microsatellite status identified by Support Vector Machine and PAM algorithms.
Probe Symbol Average expression p-value SVM* 
strength
PAM* score
Gene name MSS MSI-H MSI-H MSS
hsa-mir-223-
prec
miR-223 0.97 1.84 4.69E-02 - 0.4929 -0.3429
hsa-mir-155-
prec
miR-155 
(BIC)
0.97 1.29 2.34E-02 - 0.4439 -0.3088
AL137343 FAM84A family with 
sequence 
similarity 84, 
member A
1.51 0.45 1.07E-02 - -0.0208 0.0145
NM_004183 VMD2 vitelliform 
macular 
dystrophy 2
2.09 0.38 8.73E-03 - -0.1832 0.1274
NM_006113 VAV3 vav 3 
oncogene
1.62 0.47 5.98E-03 13.96 -0.0533 0.0371
NM_005953 MT2A metallothione
in 2A
0.57 1.92 5.93E-03 16.34 0.8995 -0.6258
AK026372 KIAA1718 1.27 0.72 5.09E-03 16.02 - -
hsa-mir-191-
prec
miR-191 1.28 1.00 4.74E-03 - 0.0377 -0.0263
NM_017726 PPP1R14D protein 
phosphatase 
1, regulatory 
(inhibitor) 
subunit 14D
1.31 0.52 3.88E-03 14.58 - -
NM_003212 TDGF1 teratocarcino
ma-derived 
growth factor 
1
1.49 0.76 3.37E-03 16.49 - -
AF273051 CCDC68 coiled-coil 
domain 
containing 68
2.21 0.84 2.49E-03 15.87 -0.0541 0.0376
NM_016328 GTF2IRD1 GTF2I repeat 
domain 
containing 1
1.49 0.87 2.13E-03 13.13 - -
NM_001657 AREG amphiregulin 2.10 0.69 1.04E-03 - -0.0725 0.0504
AB033045 KIAA1219 hypothetical 
protein 
LOC57148
1.33 0.83 8.11E-04 15.87 - -
hsa-mir-032-
precNo2
miR-032 1.17 0.91 6.48E-04 14.02 0.0732 -0.0509
NM_004485 GNG4 guanine 
nucleotide 
binding 
protein (G 
protein), 
gamma 4
1.46 0.81 6.47E-04 16.49 - -
NM_018267 H2AFJ H2A histone 
family, 
member J
1.43 0.92 6.47E-04 13.96 - -
AK000276 NKD1 naked cuticle 
homolog 1
2.47 0.77 4.55E-04 17.48 -0.1542 0.1072
NM_003878 GGH gamma-
glutamyl 
hydrolase
2.10 0.61 7.97E-05 15.87 -0.2232 0.1553
AK025215 C13ORF18 chromosome 
13 open 
reading frame 
18
2.41 0.66 4.40E-05 16.49 -0.3093 0.2152
NM_017763 RNF43 ring finger 
protein 43
2.10 0.57 2.91E-05 17.48 -0.2886 0.2008
NM_004693 K6HF cytokeratin 
type II
1.24 0.80 2.91E-05 14.6 - -Molecular Cancer 2007, 6:54 http://www.molecular-cancer.com/content/6/1/54
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PAM plot displayed a correct predictions for all the sam-
ples (Figure 2). The prediction of MSI status obtained with
72 mRNAs or 14 miRNAs signatures did not perform
equally well when tested independently. Of the 39 sam-
ples, the miRNA-only signature could correctly predict 36
samples using SVM or 33 using PAM algorithms, and the
mRNA-only signature could correctly predict 38 samples
using SVM or 39 using PAM.
Confirmation of the differential expression for some of
the signature genes was achieved by Northern blot to val-
idate miRNA expression and Real time RT-PCR to validate
expression of mRNAs. Figure 3A shows the expression of
miR-25 and miR-92 as detected by Northern blot. This
analysis confirmed that the expression of these miRNAs is
increased in MSS samples as detected by microarray anal-
ysis. Similarly, the evaluation of expression of 5 protein-
coding genes showed an overlap with the expression val-
ues obtained by microarray analysis (Figure 3B).
Discussion
We report the analysis of the combined miRNA/mRNA
expression for the discrimination of MSI-H versus MSS
human colon cancer. Because colorectal tumors character-
ized by MSI are distinct from MSS tumors in many molec-
ular aspects, such the association with the methylator
phenotype, which is responsible for MLH1 methylation,
the higher frequency of BRAF mutations and the lower fre-
quencies of KRAS, APC and TP53 mutations, MSI and MSS
colon cancers represent tumors with a different molecular
background. Thus, it is reasonable that their overall gene
expression pattern (including both mRNAs and microR-
NAs) might be affected by any of the above mentioned
mechanisms. Indeed, our analyses identified 14 miRNAs
and 451 mRNAs differentially expressed between the two
genetically distinct colon cancer classes. These results not
only indicate the existence of a mRNA/miRNA gene
expression profile able to distinguish MSS versus MSI
colon cancers, but also indicate that the combination of
miRNA/mRNA gene expression data can distinguish mic-
rosatellite instability status of human colorectal cancers
better than each RNA class independently, suggesting that
the combination of mRNA and miRNA expression may
potentially represent a general approach for improving
characterization and classification of bio-molecular and
possibly clinical traits associated with human cancer.
We also examined the prediction power of published lists
of genes differentially expressed between MSI-H and MSS
colorectal cancers [34-36] against our data set. Two pub-
lished lists describe differentially expressed genes (100
genes in the report from Di Pietro et al. 2005 [36] and 542
genes from Banerjea et al. 2004 [35]) and one is a short
list of predictors (9 genes in Kruhoffer et al. 2005 [34]).
Although these studies were all performed on Affymetrix
platforms, they generated only partially overlapping
results. The list of genes from Di Pietro et al. [36] was the
one that better correlated with our results. Twenty two of
their 100 genes were present in our list of differentially
expressed genes and, for all the remaining genes, expres-
sion tendency completely matched our data. A cluster
analysis of our data set using the 100 genes from the Di
Pietro's paper could generate a good, although not perfect,
separation between MSS versus MSI-H tumors and per-
formed well in the prediction of our samples (36 of 39
samples were correctly classified using the SVM predic-
tion) (data not shown). These results indicate that a simi-
lar set of genes emerged as differentially expressed
between MSS and MSI-H colon cancers in the Di Pietro's
and our studies, with discrepancies possibly due to small
statistical differences. Discrepancies between results
obtained with different microarray platforms are not
uncommon and are mainly determined by differences in
microarray probe sequences used to detect mRNA tran-
scripts [37] and in algorithms used for predictor genes
identification. Hence, the parallel between Di Pietro's and
our results is significant given that data were generated
using a different set of samples and a different microarray
platform, and suggests that the commonly identified set
of genes may represent the most significant differences
between MSI-H and MSS colon cancers (Additional file
6). Unfortunately, data sets from published reports were
NM_002657 PLAGL2 pleiomorphic 
adenoma 
gene-like 2
1.37 0.76 2.91E-05 19.32 - -
hsa-mir-025-
prec
miR-025 1.52 0.84 2.14E-05 17.48 - -
hsa-mir-092-
prec-13=092-
1No2
miR-092-1 1.50 0.65 1.87E-05 17.48 - -
hsa-mir-092-
prec-X=092-2
miR-092-2 1.60 0.64 1.87E-05 14.43 - -
hsa-mir-093-
prec-
7.1=093-1
miR-093-1 1.23 0.9 1.87E-05 - 0.0084 -0.0058
* SVM: Support Vector Machine; PAM: Prediction Analysis of Microarray
Table 2: Predictors of microsatellite status identified by Support Vector Machine and PAM algorithms. (Continued)Molecular Cancer 2007, 6:54 http://www.molecular-cancer.com/content/6/1/54
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Prediction of microsatellite instability Figure 2
Prediction of microsatellite instability. (A) Prediction of MSI status for 39 samples using the PAM cross-validation procedure. 
The graphical representation shows the probabilities (0.0 to 1.0) of each tumor for being MSS (pink dot) or MSI-H (blue dot). 
All tumors were correctly assigned. (B) Supervised hierarchical clustering of colon cancer samples using expression data from 
the 27 predictor mRNA/miRNA genes described in Table 2. Using the predictors for the cluster analysis, a good separation 
among colorectal cancers in MSS (red) and MSI-H (yellow) groups was achieved. Expression intensity is shown as described in 
Figure 1.Molecular Cancer 2007, 6:54 http://www.molecular-cancer.com/content/6/1/54
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Confirmation of microarray data Figure 3
Confirmation of microarray data. (A) Northern blot analysis of miRNAs miR-25 and miR-92. As expected from microarray 
data, Northern blot analysis confirmed that these miRNAs were up-regulated in MSS samples. miRNA/U6 ratio of densitomet-
ric intensities is shown below each miRNA lane. (B) Quantitative Real time RT-PCR validation of microarray results. Microar-
ray expression values of a selected panel of 5 genes differentially expressed between MSS and MSI-H groups of colorectal 
cancers were validated with quantitative real-time PCR. Values for microarray data were normalized on chip 50th percentile 
while for real-time PCR values are equal to ∆Ct*10^6.Molecular Cancer 2007, 6:54 http://www.molecular-cancer.com/content/6/1/54
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not available for cross confirmation of our list of predic-
tive genes on published microarray data.
In this report, quantitative real time PCRs for differentially
expressed mRNAs and Northern blot for differentially
expressed miRNAs were performed to validate microarray
expression data. These methods confirmed the differential
expression detected by microarray-based expression
methods. Additional evidence for the robustness of data
was the finding that the MLH1 gene is among the most
significantly (P < 0.001) down-regulated genes in MSI-H
tumors versus the MSS cancer set (Additional file 2).
Indeed, this gene represents a sort of internal control,
since it is well-known that the loss of MLH1 function,
which confers the microsatellite instability phenotype to
tumor samples, is caused by transcriptional silencing due
to promoter methylation in MSI tumors [5,6].
In addition to their role as discriminating markers of MSS
versus MSI-H tumors, some of the gene-associated func-
tions may possibly be involved in the different pheno-
types that characterize the two types of colon cancers. In
fact, analysis of the functions associated with 212 (for
which annotation was present) of the 451 differentially
expressed genes revealed that the most frequently associ-
ated classes were cell cycle, DNA replication, recombina-
tion, repair, gastrointestinal disease and immune
response (Additional file 7), suggesting that these molec-
ular differences may be responsible for traits that distin-
guish MSS and MSI-H tumors. Additional studies on the
molecular and biological functions of these differentially
expressed genes will be required to substantiate this
hypothesis.
Among the differentially expressed genes, it is interesting
to note the detection of the up-regulation of several mem-
bers of the mir-17-92 family in the MSS colon cancers.
This family includes fourteen homologous miRNAs
organized in three gene clusters [38]. Our study revealed
that, among these, miR-17-5p, miR-20, miR-25, miR-92-
1, miR-92-2, miR-93-1 and miR-106a were significantly
up-regulated in MSS versus MSI-H colon cancer. The chro-
mosomes 13 and X gene clusters were previously found
up-regulated in B-cell lymphoma [39]. It was also shown
that c-MYC promotes their transcription [40] and, inter-
estingly, enforced expression of the mir-17-92 cluster
acted with c-myc to accelerate tumour development in a
mouse B-cell lymphoma model [39]. In human solid
tumors, the chromosome 13 mir-17-92 cluster was found
up-regulated in small-cell lung cancer [41] and its ectopic
over-expression enhanced lung cancer cell growth [41].
Since these data indicate that members of the mir-17-92
family can act as oncogenes to promote cell growth and
inhibit apoptosis, our data suggests that up-regulation of
these miRNAs may have a role in the more aggressive clin-
ical behavior of MSS versus MSI-H tumors.
Conclusion
This report provides the first study on microRNA expres-
sion in MSI versus MSS colon cancer. We identified micro-
RNAs that are differentially expressed between these two
classes of tumors; moreover, the addition of microRNAs
in the molecular classifier improves the separation
between MSI and MSS cancer samples, suggesting that the
mRNA/miRNA combination could provide an improved
stratification of tumor-associated characters. Interestingly,
the most prominent class of differentially expressed miR-
NAs includes various members of the oncogenic miR-17-
92 family, suggesting that these microRNAs have a role in
bio-pathologic characteristics that distinguish MSS versus
MSI colon cancers.
Methods
Colorectal cancer samples
Samples of colorectal cancer tissue and matched normal
colonic mucosa were obtained from fresh surgical speci-
mens, frozen in liquid nitrogen, and stored at -80°C.
Thirty nine carcinomas, 23 microsatellite stable (MSS)
and 16 with high-frequency MSI (MSI-H) were analyzed
in the course of the study. The clinico-pathological fea-
tures of the tumors are detailed in Table 1. MSI status was
determined with a fluorescence-based PCR method, using
the five markers of the panel of Bethesda (BAT25, BAT26,
D2S123, D5S346, and D17S250) [42]. PCR products were
run in an ABI PRISM 377 DNA sequencer (Perkin-Elmer
Applied Biosystems Division, Foster City, CA) and ana-
lyzed by the GeneScan 3.1 version software (Perkin-
Elmer) [43]. According to the guidelines of the Workshop
of Bethesda [42], tumors showing instability at two or
more loci were classified as MSI-H and tumors without
instability at any locus as MSS. None of the tumors
included in this study exhibited instability at a single
locus (low-frequency MSI or MSI-L). All MSI-H carcino-
mas displayed instability at mononucleotide DNA
sequences (BAT25 and BAT26 markers). Tumors were also
examined for expression of the DNA mismatch repair pro-
teins MLH1 and MSH2, using the immunohistochemical
analytic procedure previously described [43]. Carcinomas
showing complete loss of nuclear MLH1 or MSH2 expres-
sion were classified as MLH1 or MSH2 negative, whereas
cancers with normal expression of MLH1 and MSH2 gene
products were classified as MLH1 and MSH2 positive. As
reported in Table 1, all MSS carcinomas demonstrated
normal nuclear expression of both MLH1 and MSH2 pro-
teins (MLH1/MSH2 positive). By contrast, of the 16 MSI-
H tumors 15 were MLH1 negative and one was MSH2
negative. As expected, MSI-H carcinomas were more fre-
quently located in the proximal colon (P < 0.001) and
poorly differentiated (P < 0.001) and more often con-Molecular Cancer 2007, 6:54 http://www.molecular-cancer.com/content/6/1/54
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tained a mucinous component (P < 0.001) with respect to
MSS tumors (Table 1). Total RNA was isolated using Tri-
zol (Invitrogen) following manufacturer's indications.
RNA integrity was assessed on a 2100 Agilent Bioanalyzer.
Only samples with intact RNA were used for the gene
expression analysis.
RNA labeling and microarray hybridization
RNA labeling and hybridization on microRNA microarray
chips was performed as previously described. [21,22]
Briefly, 5 µg of total RNA from each sample was biotin-
labeled by reverse transcription using 5' biotin end
labeled random examers oligo primer. Hybridization of
biotin-labeled cDNA was carried out on our miRNA
microarray chip (ArrayExpress accession number: A-
MEXP-86), which contains 230 human microRNA probes,
in triplicate. Hybridization signals were detected by biotin
binding of a Streptavidin – Alexa 647 conjugate using
Axon Scanner 4000B (Axon Instrument Inc. CA).
For mRNA-chip hybridization, 5 ug of total RNA were
used for the production of biotinylated cRNA. Labeled
cRNA was synthesized following the Ambion cRNA Syn-
thesis Protocol and purified using an RNeasy® Kit (Qia-
gen). cRNA yield was quantified by measuring the UV
absorbance at 260 nm. Unfragmented biotinylated cRNA
(about 50 ug) was used for hybridization on custom made
high density oligonucleotide arrays. The array was the
human 18.5K Expression Bioarray (Compugen Human
Oligo Set 1.0, http://www.labonweb.com/chips/librar-
ies.html), which contains 18,861 probes corresponding to
approximately 17,260 unique human gene clusters and
18 bacterial control probes. All probes on these microar-
rays are 65-mer oligonucleotides spotted by contacting
technologies and covalently attached to a polymeric
matrix. Microarrays were hybridized in 6 × SSPE/40% for-
mamide using a Tecan HS4800 hybridization station at
37°C for 20 hours, post-hybridization washed in 46°C
pre-warmed 0.75 × TNT (1 × TNT:0.1 M Tris-HCL, pH7.5/
0.15 M NaCL/0.05% Tween-20) at 46°C for one hour,
and processed using a direct detection method of the
biotin-containing transcripts by a Streptavidin-Alexa647
conjugate (1:500 diluted) in TNB (0.1 M Tris-HCL,
pH7.5/0.15 M NaCL/0.5% Blocking Reagent-Perk-
inElmer) at RT for 30 min. Post-staining washing in 1 ×
TNT for one hour. Processed slides were scanned using
Axon 4000B scanner (Molecular Device, CA). Image were
quantified by GenePix Pro 6.0 software.
Microarray data analysis
MiRNA-chip and mRNA chip raw data were normalized
separately using the GeneSpring software version 7.2 (Agi-
lent). Both on chip and on gene median methods were
used to normalize gene expression data. Microarray data
were then joined into one GeneSpring genome and sam-
ples were assigned to one of two groups. The comparative
analysis between MSI-H and MSS samples was carried out
using the Welch's t-test and the Benjamini & Hochberg or
Bonferroni (for a more stringent analysis) False Discovery
Rate correction. Cluster analysis was performed using the
Pearson correlation as a measure of similarity. Predictions
were made using both Support Vector Machine algorithm
and PAM software [44]. The Gene Ontology analysis of
the gene lists of interest was generated by using the web-
delivered tools of Ingenuity Pathway Analysis. Data have
been submitted to Array Express (Accession number E-
MEXP-326).
Northern blot of miRNAs
RNA samples (10 µg each) were electrophoresed on 15%
acrylamide, 7 M urea Criterion precasted gels (Bio-Rad,
Hercules, CA) and transferred onto Hybond N+ mem-
brane (Amersham Bioscience, Piscataway, NJ). Mem-
branes were hybridized with oligonucleotide probes,
corresponding to the complementary sequences of the
following mature miRNAs: miR-25 (TCA GAC CGA GAC
AAG TGC AAT G) and miR-92 (CAG GCC GGG ACA AGT
GCA ATA). Probes were 5'-end labeled using the polynu-
cleotide kinase in the presence of P32-gamma-ATP.
Hybridization was performed at 37°C in 7% SDS/0.2
mol/L Na2PO4 (pH 7.0) for 16 hours. Membranes were
washed at 42°C, twice with 2 × standard saline phosphate
(0.18 mol/L NaCl/10 mmol/L phosphate pH 7.4), 1
mmol/L EDTA (saline-sodium phosphate-EDTA, SSPE),
and 0.1% SDS and twice with 0.5 × SSPE/0.1% SDS.
Northern blots were re-hybridized after stripping the oli-
gonucleotides used as probes in boiling 0.1% SDS for 10
minutes. As a control for normalization of RNA expres-
sion levels, we hybridized blots with an oligonucleotide
probe complementary to the U6 RNA (5'-GCA GGG GCC
ATG CTA ATC TTC TCT GTA TCG-3').
Quantitative Real time PCR for mRNAs
The RT reaction was perfomed using 200 ng of total RNA
for each sample according to the manufacturer instruc-
tions (SuperScript First Strand Invitrogen). The Real Time
reactions were performed using Taqman Gene Expression
Assay on a ABI PRISM 7900HT. For each gene one set of
primers and a probe were chosen from the Applied Biosys-
tems list of TaqMan®  Gene Expression Assays.
Hs02379661_g1 for MTA2, Hs00228732_m1 for CTCL
tumor antigen, Hs00228336_m1 for C13orf18,
Hs00196125_m1 for VAV3 oncogene, Hs00914163_m1
for GGH, Hs00214886_m1 for FLJ20315. Expression
analysis was performed in triplicate for each sample.
Expression of 18S rRNA, which displayed the most con-
stant expression among tested housekeeping genes
between different samples, was used as endogenous refer-
ence control. The fold difference for each sample was
obtained using the following equation 2-dCt. Ct is theMolecular Cancer 2007, 6:54 http://www.molecular-cancer.com/content/6/1/54
Page 10 of 11
(page number not for citation purposes)
Threshold Cycle, the cycle number at which the fluores-
cence generated within a reaction crosses the threshold;
dCt = Ct average sample gene - Ct average 18S.
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